Acrivon Therapeutics, Inc. Common StockACRV

Acrivon Therapeutics is a pioneering clinical-stage oncology company advancing several potential first-in-class precision medicines guided by its unique ability to directly measure drug-regulated intracellular protein pathway activity states that underlie tumor drug sensitivity, drug resistance, and therapeutic response. The company is built around Acrivon Predictive Precision Proteomics (AP3), its cutting edge, proprietary Generative Phosphoproteomics platform. The high-throughput and high-resolution mass spectrometry-based AP3 platform incorporates a growing suite of powerful, internally-developed computational tools for generative AI analyses, including the AP3 Data Portal, the AP3 Kinase Substrate Relationship Predictor, and the AP3.

acrivon.com